Brief: Immunogen Presents Updated Findings From Cadenza Trial Of Pivekimab Sunirine
09/06/2023 08:06
June 9 (Reuters) - ImmunoGen Inc IMGN.O :
* IMMUNOGEN PRESENTS UPDATED FINDINGS FROM CADENZA TRIAL OF
PIVEKIMAB SUNIRINE IN BLASTIC PLASMACYTOID DENDRITIC CELL
NEOPLASM AT EHA 2023 CONGRESS
Source text for Eikon: ID:nBw8NwYHfa
Further company coverage: IMGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImmunoGen
See all newsBrief: Abbvie Completes Acquisition Of Immunogen
Brief: Abbvie Qtrly Adj EPS $2.79 Vs LSEG IBES Estimate $2.77
Brief: Immunogen Says German Federal Cartel Office Approved Merger With Abbvie Unconditionally
Ambrx Biopharma surges on J&J's buyout announcement
Street View: BioMarin-Elliott settlement likely eases investor frustration